Heart Failure (HF) Market Study 2020: Epidemiology, Treatment, Drugs and Companies (2017-2028) - ResearchAndMarkets.com

DUBLIN--()--The "Heart Failure (HF) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of HF in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Heart Failure (HF) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Epidemiology

According to the publisher, the total prevalent cases of HF in the 7MM was found to be 12,026,384 in 2017. The prevalent cases of HF in the 7MM are expected to increase during the study period of 2017-2028. Also, in 7MM the highest number of prevalent cases were observed in the US with 6,192,189 cases in 2017.

The disease epidemiology covered in the report is segmented by:

  • Prevalent Population of Heart Failure
  • Diagnosed Prevalent Population of Heart Failure
  • Gender-specific diagnosed prevalent cases of Heart Failure
  • Age-specific diagnosed prevalent cases of Heart Failure
  • NYHA class-specific diagnosed prevalent cases in the United States
  • Diagnosed prevalent cases of Heart Failure with Ejection Fraction
  • Diagnosed Prevalent cases of Heart Failure

A study conducted by Jackson et al. (2018) in the United States, HF affects approximately 6.5 million adults, and lifetime risk of HF is estimated to be 1 in 5 at 40 years of age. The incidence of HF increases with age, and HF prevalence in the aging US population is projected to increase by 46% between 2012 and 2030. Among hospitalizations for primary HF, the most common comorbid diagnoses were hypertension (72%), IHD (56%), diabetes mellitus (48%), chronic kidney disease (47%), and AF (43%). Among deaths with comorbid HF, the most common underlying causes were IHD (44%), hypertension (21%), and chronic obstructive pulmonary disease (21%).

As per the National Health Services (NHS), researchers compared the number of heart failure cases in the UK from 2002 to 2014. It was found that new cases of heart failure increased by 12% from 2002 to 2014. Instead, it was observed at how differences in socioeconomic status affected the number of heart failure cases in the UK. Out of the sample, 93,074 people were diagnosed with heart failure: 45,647 women and 47,427 men.

Drug Chapters

The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of HF and awareness of the disease. The overall dynamics of the HF market is anticipated to change in the coming years owing to the expected launch of emerging therapies that are already approved in specific regions but are expected to be launched in other regions as well. The major key players such as Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme Corp, and others will significantly increase the market during the forecast period (2019-2028).

Market Outlook

According to the publisher, the market for HF in the 7MM was found to be approximately 5,148.32 Million in 2017.

Drugs Uptake

The dynamics of HF market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as empagliflozin (Boehringer Ingelheim/Eli Lilly and Company), vericiguat (Merck Sharp & Dohme Corp./Bayer), AZD4831 (AstraZeneca), dapagliflozin/farxiga (AstraZeneca), omecamtiv mecarbil (Amgen/Cytokinetics/Servier), RT-110 (Renova Therapeutics), RT-400 (Renova Therapeutics), BMS-986231 (Bristol-Myers Squibb), Elamipretide (Stealth BioTherapeutics), Firibastat (Quantum Genomics), Macitentan (Actelion Pharmaceuticals), in the HF market by 2028.

Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Companies Mentioned

  • Actelion Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cytokinetics
  • Eli Lilly & Company
  • Merck Sharp & Dohme Corp.
  • Novartis
  • Quantum Genomics
  • Renova Therapeutics
  • Servier
  • Stealth BioTherapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6ofqta

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900